Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00287547
Status:
COMPLETED
Last Update Posted:
2011-04-25
First Post:
2006-02-06
Brief Title:
Phase II Randomized Double-Blind Placebo-Controlled Study of BMS-188667 CTLA4Ig in Patients With Psoriasis Vulgaris
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Phase II Randomized Double-Blind Placebo-Controlled Study of BMS-188667 CTLA4Ig in Patients With Psoriasis Vulgaris
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety pharmacokinetics and clinical activity and immunogenicity of BMS-188667 CTLA4Ig in subjects with psoriasis vulgaris
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None